Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19

NCT04347681 is registered in ClinicalTrials.gov with King Fahad Specialist Hospital Dammam as lead sponsor.

NCT NCT04347681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04347681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19
Lead sponsor
King Fahad Specialist Hospital Dammam
Phase
Phase 2
Overall status
Completed
Start date
April 18, 2020
Completion date
November 16, 2020
Enrollment
575 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

convalescent plasma for covid 19